Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

HPP 737

Next Previous
Drug Profile

HPP 737

Alternative Names: HPP-737

Latest Information Update: 28 Mar 2025

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator vTv Therapeutics LLC
  • Developer Newsoara Biopharma; vTv Therapeutics LLC
  • Class Anti-inflammatories; Antipsoriatics; Skin disorder therapies; Small molecules
  • Mechanism of Action Type 4 cyclic nucleotide phosphodiesterase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes
  • Available For Licensing Yes

Highest Development Phases

  • Phase III Atopic dermatitis; Chronic obstructive pulmonary disease; Psoriasis

Most Recent Events

  • 28 Mar 2025 No recent reports of development identified for phase-I development in Chronic-obstructive-pulmonary-disease in USA (PO, Capsule)
  • 30 Aug 2024 Newsoara Biopharma plans a clinical study for Psoriasis (In vounteers) in China (PO) in August 2024 (NCT06584058)
  • 30 Jun 2024 HPP 737 licensed to Newsoara Biopharma worldwide

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top